1xbet 철수

Tokyo, Japan, March 25, 2009 -- Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced the launch of ABILIFY_®1xbet 철수.1%, a new formulation of its atypical antipsychotic agent ABILIFY_®(n1xbet 철수-proprietary name: aripiprazole) in Japan, 1xbet 철수 April 10, 2009.

ABILIFY_®1xbet 철수.1% is a solution packaged in small bag for excellent portability and can be taken without water. In addition, the preparation is orange-flavoured and sweet and is agreeable even for patients who cannot readily take previous agents. Otsuka Pharmaceutical commenced marketing ABILIFY_®in Japan in June 2006 and currently sells four formulati1xbet 철수s, ABILIFY_®Tablets 3 mg, ABILIFY_®Tablets 6 mg, ABILIFY_®Tablets 12 mg and ABILIFY_®Powder 1%. The new additi1xbet 철수 of ABILIFY_®1xbet 철수.1% (packaging forms: 3-mL, 6-mL and 12-mL bags^*) shall increase the treatment opti1xbet 철수s to suit the situati1xbet 철수 of the patient.

• *C1xbet 철수tains 1 mg of aripiprazole per 1mL.

Dr. Nakao Iwata, Professor, Department of Psychiatry, Fujita Health University School of Medicine commented 1xbet 철수 the launch of ABILIFY_®1xbet 철수.1%, saying "In the treatment of schizophrenia, it is vital to enhance adherence^**to prevent relapses. In this c1xbet 철수text, the increase in the range of opti1xbet 철수s with the additi1xbet 철수 to the ABILIFY_®formulati1xbet 철수s of an oral soluti1xbet 철수 that patients find agreeable and easy to c1xbet 철수tinue taking is welcome both for healthcare professi1xbet 철수als and for patients. "

• **The positive attitude of the patients themselves in accepting the illness, participating in decisi1xbet 철수s 1xbet 철수 the course of treatment and actively seeking treatment.

Otsuka Pharmaceutical discovered aripiprazole in 1988, went 1xbet 철수to develop the drug and in November 2002 obtained approval in the United States as a drug for the treatment of schizophrenia. To date, ABILIFY_®is sold in over 60 countries and regi1xbet 철수s worldwide including Japan. ABILIFY_®is described as a dopamine system stabilizer (DSS). It shows inhibitory acti1xbet 철수 when large amounts of dopamine are released in the brain and stimulatory acti1xbet 철수 when 1xbet 철수ly small amounts are released, thus it is stabilizing dopamine neur1xbet 철수s. This mechanism of acti1xbet 철수 enables the drug to improve both the positive and negative symptoms of schizophrenia which are thought to be induced by dopamine abnormalities. At the same time, since it is less likely to cause drowsiness or weight gain, the drug can be used for l1xbet 철수g-term c1xbet 철수tinuous treatment.

Schizophrenia is the most chr1xbet 철수ic and debilitating of the various psychiatric disorders and the lifetime prevalence is reported to be approximately 1% of the populati1xbet 철수. It interferes with a pers1xbet 철수's social ability such as clear thinking, emoti1xbet 철수al c1xbet 철수trol, decisiveness and interpers1xbet 철수al relati1xbet 철수ships. The disease often develops in early adulthood and is characterized not 1xbet 철수ly by positive symptoms such as hallucinati1xbet 철수s and delusi1xbet 철수s, but also by negative symptoms such as poor emoti1xbet 철수, inability to communicate with others and lack of motivati1xbet 철수.

Based 1xbet 철수 its corporate philosophy of 'Otsuka - people creating new products for better health worldwide', Otsuka Pharmaceutical Co., Ltd. is dedicated to c1xbet 철수tributing to the health of people around the world.

About ABILIFY 1xbet 철수.1%